Carrillo-Esper R, González-Salazar JA, Calvo-Carrillo B

Language: Spanish
References: 68
Page: 71-76
PDF size: 460.86 Kb.

ABSTRACT

Arginine-vasopresin (VP), also known as the antidiuretic hormone, is essential for water homeostasis. Its synthesis and liberation depends on regulation of osmotic, hypovolemic, hormonal, and nonosmotic stimuli. It has been demonstrated that it is key for maintenance of cardiovascular homeostasis through vasomotor regulation, the determinant of systemic vascular resistance and mean arterial pressure, a process acting through V1 receptors. Shock state with refractary vasodilation seen in sepsis, systemic inflamatory response, hypovolemia, cardiac arrest, polytrauma, etc., is characterized by an initial phase of liberation and increased levels of VP followed by a second phase caracterized by inappropirately low levels of this hormone that are associated with refractariness to management with volume, inotropics, and vasopressors. It has been demonstrated in clinical and experimental studies that exogenous VP treatment under this condition increases systemic vascular resistance, perfusion pressure, and oxygen supply to peripheral tissues, which makes it possible to decrease and to suspend vasopressors and also to increase survival.

REFERENCES

1. Errington ML, Rocha M, Silva E Jr. The secretion and clearance of vasopressin during the development of irreversible haemorrhagic shock. Proc Physiol Soc 1971;23:43P-45P.

2. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-1125.

3. Wenzel V, Prengel AW, Maier C, et al. Vasopressin improves vital organ blood flow after prolonged cardiac arrest with postcountershock pulseless electrical activity in pigs. Crit Care Med 1999;27:486-492.

4. Ridell DC, Mallonee R, Philips JA, et al. Chromosomal assignment of human sequences encoding arginine vasopressin-neurophysin II and growth hormone releasing factor. Somat Cell Mol Genet 1985;11:189-195.

5. Robertson GL. The regulation of vasopressin function in health and disease. Prog Horm Res 197;33:333-385.

6. Physiological pathways regulating the activity of magnocellular neurosecretory cells. Prog Neurobiol 1999;57:625-655.

7. Sklar AH, Schrier R. Central nervous system mediators of vasopressin release. Physiol Rev 1983;63:1243-1280.

8. Bourque CW, Oliet SH, Richard D. Osmoreceptors, osmoreception and osmoregulation. Front Neuroendocrinol 1994;15:231-274.

9. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979;236:F321-F332.

10. Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int 1976;10:25-37.

11. Thrasher TN. Baroreceptor regulaton of vasopressin and renin secretion: low-pressure versus high-pressure receptors. Front Neuroendocrinol 1994;15:157-196.

12. Wang BC, flora-Ginter G, Leadley RJ Jr, et al. Ventricular receptors stimulate vasopressin release during hemorrhage. Am J Physiol 1988;254:R204-R211.

13. Reid IA. Role of nitric oxide in the regulation of renin and vasopressin secretion. Front Neuroendocrinol 1994;15:351-383.

14. Day TA, Randle JC, Renaud LP. Opposing alpha-and beta-adrenergic mechanisms mediate dose-dependent actions of norepinephrine on supraoptic vasopressin neurones in vivo. Brain Res 1985;358:171-179.

15. Randle JC, Bourque CW, Renaud LP. Alpha1-adrenergic receptor activation depolarizes rat supraoptic neurosecretory neurons in vitro. Am J Physiol 1986:251:R569-R574.

16. Kovacs L, Robertson GL. Syndrome of inappropriate antiduresis. Endocrinol Metab Clin North Am 1992;21:859-875.

17. Share L, Kimura T, Matsui K, et al. Metabolism of vasopressin. Fed Proc 1985;44:59-61.

18. Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. J Endocrinol 1998;156:223-229.

19. Bichet D. Vasopressin receptors in health and disease. Kidney 1996;49:1706-1711.

20. Riphagen CL, Pttman QJ. Arginine vasopressin as a central neurotransmitter. Fed Proc 1986;45:2318-2322.

21. Czaczkes JW. Physiologic studies of antidiuretic hormone by its direct measurement in human plasma. J Clin Invest 1964;43:1625-1640.

22. Morton JJ, Padfield PL, Forsling ML. A radioimmunoassay for plasma arginine-vasopressin in man and dog: application to physiological and pathological states. J Endocrinol 1975;65:411-424.

23. Arnauld E, Czernichow P, Fumoux F, et al. The effects of hypotension and hypovolaemia on the liberation of vasopressin during hemorrhage in the unanaesthetized monkey (Macaca mulatta). Pflugers Arch Eur J Physiol 1977;371:193-200.

24. Cowley AW Jr, Switzer SJ, Guinn MM. Evidence and quantification of the vasopressin arterial pressure control system in the dog. Circ Res 1980;46:58-67.

25. Brackett DJ, Schaefer CF, Wilson MF. The role of vasopressin in the maintenance of cardiovascular function during early endotoxin shock. Adv Shock Res 1983;9:147-156.

26. Zerbe RL, henry DP, Robertson GL. Vasopressin response to orthostatic hypotension: etiologic and clinical implications. Am J Med 1983;74:265-271.

27. Schwartz J, Reid IA. Role of vasopressin in blood pressure regulation in conscious water-deprived dogs. Am J Physiol 1983;244:R74-R77.

28. Mohnring J, Glanzer K, Maciel JA Jr, et al. Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension. J Cardiovasc Pharmocol 1980;2:367-376.

29. Wilson MF, Brackett DJ, Tompkins P, Benjamin B, Archer LT, Hinshaw LB. Elevated plasma vasopressin concentrations during endotoxin and E. Coli shock. Adv Shock Res 1981;6:15-26.

30. Baker CH, Sutton ET, Zhou Z, Dietz JR. Microvascular vasopressin effects during endotoxin shock in the rat. Circ Shock 1990;30:81-95.

31. Brackett DJ, Schaefer CF, Wilson MF. The role of vasopressin in the maintenance of cardiovascular function during early endotoxin shock. Adv Shock Res 1983;9:147-56.

32. Wilson MF, Brackett DJ, Hinshaw LB, et al. Vasopressin release during sepsis and septic shock in babonsand dogs. Surg Gynecol Obstet 1981;153:869-872.

33. Errington ML, Rocha e Silva M Jr. The secretion and clearance of vasopressin during the development of irreversible hemorrhagic shock. J Physiol (Lond) 1971;217:43P-45P.

34. Brackett DJ, Schaefer CF, Tompkins P, et al. Evaluation of cardiac output, total peripheral vascular resistance, and plasma concentrations of vasopressin in the conscious, unrestrained rat during endotoxemia. Circ Shock 1985;17:273-284.

35. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997;25:1279-1282.

36. Argenziano M, Choudhri AF, Oz MC, et al. Prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997;96:II-286-290.

37. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. Thorac Cardiovasc Surg 1998;116:973-980.

38. Brackett DJ, Schaefer CF, Wilson MF. The role of vasopressin in the maintenance of cardiovascular function during early endotoxin shock. Adv Shock Res 1983;9:147-156.

39. Rurak DW. Plasma vasopressin levels during hemorrhage in mature and immature fetal sheep. J Dev Physiol 1979;1:91-101.

40. Abid O, Akca S, Haji-Michael P, et al. Strong vasopressor support may be futile in the intensive care unit patient with multiple organ failure. Crit Care Med 2000;28:947-949.

41. Matsuoka T, Wisner D. Hemodynamic and metabolic effects of vasopressin blockade in endotoxin shock. Surgery 1997;121:162-173. 41. Bartelstone HJ, Nasmyth PA. Vasopressin potentiation of cathecholamine actions in dog, rat, cat, and rat aortic strip. Am J Physiol 1965;208:754-762.

42. Medina P, Noguera I, Aldasoro M, et al. Enhancement by vasopressin of adrenergic responses in human mesenteric arteries. Am J Physiol 1997;272:H1087-H1093.

43. Wakatsuki t, Nakaya TY, Inoue I. Vasopressin modulates K-channel activities of cultured smooth muscle cells from porcine coronary artery. Am J Physiol 1992;263:H491-H496.

44. Umino T, Kusano E, Muto S, et al. AVP inhibits LPS- and IL-1B-stimulated NO and cGMP via V1 receptor in cultured rat mesangial cells. Am J Physiol 1999;276:F433-F441.

45. Nambi P, Whitman M, Gessner G, Ajyar N, Crooke ST. Vasopressinmediated inhibition of atrial natriuretic factor-stimulated cGMP accumulation in an established smooth muscle cell line. Proc Natl Acad Sci USA 1986;83:8492-5.

46. Lindberg JS, Copley JB, Melton K, et al. Lysine vasopressin in the treatment of refractory hemodialysis-induced hypotension. Am J Nephrol 1990;10:269-275.

47. Overand PT, Teply JF. Vasopressin for the treatment of refractory hypotension after cardiopulmonary bypass. Anesth Analg 1998;86:1207-1209.

48. Gold JA, Cullinane S, Chen J. Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Crit Care Med 2000;28:249-252.

49. Morales D, Madigan U, Cullinane S, et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 1999;100:226-9.

50. Chen JM, Cullinane S, Spanier TB, et al. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation 1999;100:Suppl II:II-244-II-246.

51. Lindner KH, Prengel AW, Brinkmann A, Strohmenger HU, Lindner IM, Lurie KG. Vasopressin administration in refractory cardiac arrest. Ann Intern Med 1996;124:1061-4.

52. Morales DL, Gregg D, Helman DN, et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 2000;69:102-106.

53. Chen JM, Cullinane S, Spanier TB, et al. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation 1999;100:II244-II246.

54. Gold J, Cullinane S, Chen J, et al. Vasopressinm in the treatment of milrinone-induced by hypotension in severe heart failure. Am J Cardiol 2000;85:506-588, A11.

55. Rosenweig EB, Starc TJ, Chen JM, et al. Intraenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 1999;100:II182-II186.

56. Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001;29.

57. Kurtzman NA, Rogers PW, Boonjarern S, et al. Effect of infusion of phamacologic amounts of vasopressin on renal electrolyte excretion. Am J Physiol 1975;228:890-894.

58. Shelly MP, Greatorex R, Calne RY, et al. The physiological effects of vasopressin when used to control intra-abdominal bleeding. Intensive Care Med 1988 14:526-531.

59. Voelckel WG, Lindner K, Wenzel V, et al. Effects of vasopressin and epinephrine on splanchnic blood flow and renal function during and after cardiopulmonary resuscitation in pigs. Crit Care Med 2000;28:

60. Lindner KH, Prengel AW, Pfenninger EG, et al. Vasopressin improves vital organ blood flow during closed-chest CPR in pigs. Circulation 1995;91:215-221.

61. Prengel AW, Lindner KH, Keller A. Cerebral oxygenation during cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Stroke 1996;27:1241-1248.

62. Lindner KH, Prengel AW, Brinkmann A, et al. Vasopressin administartion in refractory cardiac arrest. Ann Intern Med 1996;124:1061-1064.

63. Cain BS, Cain JS. Vasopressin in advanced cardiac life support? Crit Care Med 2001;29.

64. Morris DC, Grzybowski M, Martin GB, et al. Vasopressin can increase coronary perfusion pressure during hyuman cardiopulmonary resuscitation. Acad Emerg Med 1997;4:878-883.

65. Wenzel V, Krismer AC, Miller EA, et al. Repeated administation of vasopressin but not epinephrine maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation in pigs. Circulation 1999;99:1379-1384.

66. Wenzel V, Augenstein S, Voelckel W, et al. Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. Crit Care Med 1999;27:1565-1569.

67. Lindner KH, Strohmenger HU, Prengel AW, et al. Rrandomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997;349:535-537.

68. Voelckel WG, Wenzel V, Bonatti J, et al. Effects of vasopressin and epinephrine on splanchnic blood flow and renal function during and after cardiopulmonary resuscitation in pigs. Crit Care Med 2000;28:1083-1088.